[Market Focus] Geninus Rises on 62% Sales Growth in First Half

Geninus is showing strong performance in early trading.

As of 9:03 a.m. on August 19, Geninus was trading at 1,774 won, up 8.17% (134 won) from the previous day.

Geninus appears to have boosted investor sentiment by posting strong results in the first half of the year, after restructuring its business to focus on artificial intelligence (AI) drug development solutions and pharmaceutical company data. In the first half of this year, Geninus recorded sales of 5.2 billion won. This represents a 62.5% increase compared to the same period last year and exceeds 80% of last year’s total annual sales. GxD Inc., a subsidiary that had no sales until last year, achieved its first revenue of 1.7 billion won through collaborations with hospitals and pharmaceutical companies in Japan.

There are also expectations that Geninus will gain further momentum in entering the global AI drug development market. Currently, Geninus is reportedly discussing ways to supply its AI drug development solution, 'IntelliMed,' to global pharmaceutical companies either by listing it on the Amazon Web Services (AWS) Marketplace or by offering it jointly with AWS.

This content was produced with the assistance of AI translation services.